Research Tools; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.